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Abstract: Background. Respiratory syncytial virus (RSV) is a
common community-acquired pathogen responsible for a substantial
disease burden in adults. We investigated the outcomes after RSV
infection in hospitalized adults over a 3-year period.
Methods. This single-center, retrospective study identified 174
patients hospitalized with RSV upper or lower respiratory tract
infection (LRTI) between January 1, 2009 and June 30, 2012. Clinical
data were extracted from medical records. The primary outcome
analyzed was all-cause mortality, defined as death during the index
hospital admission. Subjects were divided into 3 groups for
comparison: hematopoietic stem cell transplant (HSCT) patients,
solid organ transplant (SOT) patients, and non-transplant patients.
Results. In our study, 41/174 (23.6%) were HSCT recipients and 28/
174 (16.1%) were SOT recipients. Twelve of 174 (6.9%) died. Death
occurred in 2/41 (4.9%) HSCT and 3/28 (10.7%) SOT recipients,
compared to 7/106 (6.6%) non-transplant patients. When compared
to the non-transplant cohort, HSCT and SOT were not found to be
significant risk factors for mortality (P = 0.685 and 0.645,
respectively). In multivariate logistic regression, age >60 was
associated with mortality (P = 0.019), while lymphopenia on
admission trended toward an association with death (P = 0.054).
HSCT patients were less likely to be admitted to an intensive care
unit (odds ratio [OR] 0.26, P = 0.04), but were significantly more
likely to receive ribavirin therapy (OR 11.62, P < 0.0001).
Conclusion. Adults hospitalized with RSV LRTI are at significant risk
of mortality, and this risk may be increased in patients age >60 or
with lymphopenia on admission. This study did not identify any
significant increased mortality or morbidity associated with RSV
infection in immune suppressed transplant recipients vs. patients
who had not received a transplant.
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Respiratory syncytial virus (RSV) is a single-stranded,
enveloped RNA virus of the paramyxoviridae family
that causes respiratory infection in 3–20% of adults
annually, rivaling the incidence of influenza A infection
(1–6).
Multiple studies have identified risk factors for
severe RSV infection in adults including advanced
age, poor functional status, underlying cardiopulmo-
nary disease, and significant immunocompromised
state (7, 8). Hematopoietic stem cell transplant (HSCT)
recipients represent a particularly high-risk group, with
recent studies showing significant but highly variable
mortality rates of 5–80% in patients with lower respira-
tory tract infection (LRTI) (9–16). In comparison,
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studies involving solid organ transplant (SOT) recipi-
ents have only demonstrated significant mortality in
lung transplant recipients with LRTI (0–20%), although
published data for other organs are limited (14, 17, 18).
However, measured outcomes of transplant recipients
infected with RSV in prior studies are heterogeneous,
as are treatment approaches. Unlabeled use of ribavi-
rin, a guanosine analog, has been used as a primary
therapy for RSV; however, owing to a lack of large
randomized control trials, currently there is no stan-
dardized treatment strategy in these at-risk populations.
Therefore, in this study, we present a retrospective
analysis of 174 RSV assay-confirmed cases, including
both transplanted and non-transplanted adults, between
2009 and 2012 at the University of Michigan Hospital,
designed to better characterize risk factors leading to
severe infection and death, as well as outcomes of RSV
LRTI in a diverse hospitalized population.
Patients and methods
This study was conducted at the University of Michigan
Hospital, a 980-bed tertiary care medical center, where
approximately 350 SOTs and 250 HSCTs are performed
each year. After institutional review board approval,
subjects were identified using retrospective data of
positive RSV viral culture, antigen assay (Diagnostic
Hybrids, Athens, Ohio, USA), or polymerase chain
reaction (PCR) assay (Prodesse ProFlu+; Hologic,
Bedford, Massachusetts, USA) (19) obtained between
January 1, 2009 and June 30, 2012, encompassing 4
sequential RSV seasons. In total, 218 adult patients
were identified; 44 of these patients were diagnosed
and managed as outpatients, and were therefore
excluded from analysis, leaving 174 hospitalized
subjects for inclusion.
Data related to the hospitalization and outcomes of
each patient were abstracted from the electronic
medical record system. Demographic data included
age, gender, history of malignancy or chronic lung
disease (such as chronic obstructive pulmonary dis-
ease, interstitial lung disease, pulmonary fibrosis, or
bronchiectasis), ongoing chemotherapy, receipt of
autologous or allogeneic HSCT, and receipt of SOT.
Clinical data abstracted from the medical record
included interval time from HSCT or SOT to diagnosis
of RSV infection, presenting symptoms, and oxygen
saturation at time of admission, chest radiographic
findings (x-ray and computed tomography), admission
to intensive care unit during hospitalization, mechanical
ventilation, pulmonary co-infection(s), receipt and dura-
tion of oral and/or inhaled ribavirin, and duration of
hospitalization. Subjects were determined to have had
upper respiratory tract infection (URTI) or LRTI based
on these data. LRTI was present if either of the
following criteria were met: (i) pulse oximetry <90%
or requirement of supplemental oxygen therapy on
admission with respiratory symptom(s) of infection and
radiographic evidence of LRTI and positive nasopha-
ryngeal or throat RSV assay, or (ii) bronchoalveolar
lavage specimen positive for RSV. Any subject not
meeting LRTI criteria but with an upper respiratory
sample positive for RSV and concurrent respiratory
tract infection symptoms was defined as having URTI.
All testing for RSV at our hospital during the study
period was performed at the discretion of the treating
physician(s).
Data were obtained from the date of hospital admis-
sion until the date of discharge. The primary outcome
analyzed was all-cause mortality, defined as death
during the index hospital admission. To study the
predictors of death (covariate-adjusted), a logistic
regression model was used. Covariates included in
the model were age, gender, absolute lymphocyte
count (ALC) on admission, transplant status, diagnosis
of chronic lung disease, fever, computed tomography
findings, and URTI symptoms. Age at diagnosis was
split into 2 categories: >60 years and ≤60 years.
Secondary analysis was performed with subjects split
into SOT, HSCT, and non-transplanted cohorts. Multi-
variate logistic regression models for death were fitted
separately in these 3 groups. Because of the small
sample size, some covariates did not have enough
variation and, thus, were excluded from the model. The
standard significance level (0.05) was applied to delin-
eate statistically significant from non-significant effects.
In addition, in order to describe observed patterns in
the number of RSV diagnoses over calendar time,
curves displaying RSV incidence (counts of diagnoses
vs. time) were plotted by transplant type. All statistical
analyses were carried out using SAS v9.2 (SAS Insti-
tute, Cary, North Carolina, USA).
Results
During the study period, 174 cases of RSV infection
occurred in hospitalized adult patients. Of these, 152
cases (87.3%) were identified by positive nasopharyn-
geal swab (150 PCR assay, 2 viral culture); 13 cases
(7.5%) identified by bronchoalveolar lavage fluid (10
PCR assay, 3 viral culture); and 9 cases (5.2%) identified
by sputum culture/tracheal aspirate (4 PCR assay, 3
RSV antigen, 2 viral culture). Epidemiologic curves by
transplant type are shown in Figure 1 and include both
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outpatient and inpatient subjects. Fifteen RSV cases
were detected in the 2009 season, 64 cases in 2009–
2010, 72 cases in 2010–2011, and 67 cases in 2011–2012.
Of note, the University of Michigan microbiology
laboratory transitioned to PCR-based testing for RSV
in September 2009 and, thereafter, a consistently
higher number of cases were identified each season.
The periodic pattern of the curves and the time of onset
of infection among SOT, HSCT, and non-transplant
cohorts were similar in each season, with cases
primarily identified between January and May.
Patient characteristics of the 174 subjects are listed
in Table 1. Of these, 41 subjects (23%) were HSCT
recipients, 28 subjects (16%) were SOT recipients, and
106 subjects (61%) were not transplant recipients. The
SOT cohort included 16 lung, 8 kidney, 3 heart, 1 liver,
and 1 kidney/pancreas transplant recipient. One
patient received both a HSCT and SOT. LRTI was
present in 121 subjects (69.5%). The average length of
stay at the hospital was 9.3  11.3 days; 37 subjects
(21.2%) required intensive care unit admission, and 17
(9.8%) received mechanical ventilation. The non-trans-
plant cohort was significantly older than the HSCT
cohort (62.1 years vs. 53.8 years, P = 0.001). Subjects
with SOT and non-transplanted subjects were both
significantly more likely to have underlying chronic
lung disease than were HSCT subjects (P = 0.003).
The mean durations from date of HSCT or SOT until
RSV infection were 2.60 years and 6.05 years, respec-
tively.
Twelve subjects (6.9%) died during hospitalization. 2
subjects were HSCT recipients, 3 were SOT recipients,
and 7 were not transplant recipients. All deaths
occurred in patients with LRTI, resulting in a mortality
rate of 10% (12/121) in this subset of patients. Results
for the logistic regression model of death are listed in
Table 2. Death risk was significantly greater for
subjects >60 years of age, with a covariate-adjusted
odds ratio (OR) of 8.41 (P = 0.019) compared with
subjects <60 years of age. Each 1 unit (100 cells/lL)
increase in ALC on admission was estimated to
decrease the odds of in-hospital death by approximately
75% (OR = 0.24), with the effect approaching statistical
significance (P = 0.051). No other covariate effects
approached significance for risk of death.
Results based on logistic regression models of death
in HSCT recipients (n = 41) and SOT recipients
(n = 28) did not identify any covariates associated
with mortality. For non-transplant subjects, higher
ALC was significantly associated with lower odds of
death (OR = 0.09; P = 0.046). Specifically, each 100
cell/lL increase in ALC resulted in a >90% decrease in
the risk of death. Age >60 showed borderline signif-
icance, with a trend toward greater risk of mortality
(OR = 11.4; P = 0.065); i.e., the odds of death in
patients age >60 was more than 11 times greater than
Fig. 1. Epidemiologic curve of confirmed cases of respiratory syncytial virus infection by transplant type: 2009–2012. SOT, solid organ
transplant; SCT, stem cell transplant.
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that of patients age ≤60, adjusting for all other
covariates.
Ribavirin therapy (either inhaled or systemic) was
administered in 39 (22.4%) patients. Overall, 23/40
(56.1%) of HSCT recipients received some form of
ribavirin therapy, compared with 6/27 (22.2%) of SOT
recipients, and 10/107 (9.3%) of non-transplant recipi-
ents. In those who received ribavirin therapy, LRTI was
identified in 16/22 (72.7%) HSCT recipients, in 5/6
(83.3%) SOT recipients, and in 8/10 (80%) non-trans-
plant recipients. The average duration of ribavirin
therapy was 7.8 days (range 1–15 days, median
7 days). In ribavirin-treated patients, 5/39 (12.8%)
received both inhaled and oral ribavirin, all 5 of whom
were HSCT recipients, with 1 in-hospital death. Thirty-
four of 39 patients (87.2%) received only oral ribavirin
(18 HSCT recipients, 6 SOT recipients, and 10
non-transplanted subjects), with 3 in-hospital deaths
(1 HSCT recipient, 1 SOT recipient, 1 non-transplant).
Discussion
RSV has been shown to be an important cause of
respiratory infection in transplant recipients with sig-
nificant associated morbidity and mortality. In this
single-center study, we retrospectively analyzed the
impact of RSV infection in a diverse hospitalized adult
population that included HSCT, SOT, and non-trans-
plant patients from 2009 to 2012. The timing of RSV
infection in each season did not differ between trans-
plant and non-transplant patients. A dramatic and
sustained increase was seen in the number of cases
identified between the 2009 RSV season and the
Baseline characteristics of study patients
Characteristics
Inpatients with SCT
(n = 41)1
Inpatients with SOT
(n = 28)1
Inpatients without
transplant (n = 106)
Gender, n (%)
Female 16 (39.02) 10 (35.71) 75 (70.75)
Male 25 (60.98) 18 (64.29) 31 (29.25)
Age, mean years  SD 53.78  11.82 55.00  15.12 62.08  19.83
Chronic lung disease, n (%) 4 (9.76) 11 (39.29) 36 (33.96)
Length of stay, mean days  SD 11.44  13.51 9.29  11.51 8.49  10.30
ICU admission, n (%) 6 (14.63) 5 (17.86) 26 (24.53)
Mechanical ventilation, n (%) 3 (7.32) 4 (14.29) 10 (9.43)
Death, n (%) 2 (4.88) 3 (10.71) 7 (6.60)
Fever, n (%) 22 (53.66) 13 (46.43) 45 (42.45)
Respiratory infection, n (%)
Upper 11 (26.83) 10 (35.71) 32 (30.19)
Lower 30 (73.17) 18 (64.29) 74 (69.81)
Lymphocyte count2, mean  SD 1234  831 860  528 1208  1059
Abnormal CT findings, n (%)
Yes 19 (46.34) 8 (28.57) 23 (21.70)
No 7 (17.07) 5 (17.86) 7 (6.60)
CT scan not performed 15 (36.59) 15 (53.57) 76 (71.70)
Treated with ribavirin, n (%) 23 (56.10) 6 (21.43) 10 (9.43)
Duration from transplant to
infection, mean years  SD
2.60  2.47 6.05  6.69 NA
1One subject had both SCT and SOT, and thus was counted in both groups.
2Lymphocyte count data not available for 5 subjects.
SCT, stem cell transplant; SOT, solid organ transplant; SD, standard deviation; ICU, intensive care unit; CT, computed tomography; NA, not
applicable.
Table 1
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following seasons, which may be attributable to multi-
ple factors. The improved sensitivity of the new testing
platform, over that of viral culture and antigen-based
assays, may have had an impact, as has been well
described (20, 21). More significantly, however, our
transition to a PCR platform allowed bundled testing for
influenza and RSV, whereas previously, RSV testing
required a separate specific order in a patient with an
influenza-like illness, likely leading to increased screen-
ing for RSV in adults overall. Within the transplant
cohorts, patients were typically infected several years
after their transplant, reflecting the risk for acquisition
of RSV as a community-acquired rather than nosoco-
mial infection.
We did not identify independent risk factors for
mortality from RSV infection among the transplant
populations. Among the entire study population, only
age >60 years was significantly associated with a risk of
death from RSV infection. Among the individually
analyzed cohorts of HSCT, SOT, and non-transplant
patients, age >60 years increased the odds of mortality,
but only approached significance in non-transplant
recipients (OR = 11.4; P = 0.065). Analysis of other
potential risk factors associated with mortality found
decreased odds of death of 13.4% (OR = 0.866) per 100
cell increase in ALC among the entire study population,
with this effect also approaching statistical significance
(P = 0.051). When stratified by HSCT, SOT, and non-
transplant cohorts, ALC was found to be a significant
risk factor of death only in non-transplant patients
(OR = 0.092; P = 0.045). A recent study of RSV in 181
HSCT recipients showed 24% of patients progressing to
LRTI and identified risk factors for progression includ-
ing smoking, high-dose total body irradiation, and ALC
≤100 mm3 at the onset of URTI symptoms (22). Many
previous studies have commented on the increased risk
of progressive infection and mortality in patients with
lymphopenia (ALC ≤100 mm3) and older age (11,
22–25).
In this cohort, mortality was 6.9% (12/174 patients).
All 12 patients who died had evidence of LRTI at the
time of admission. HSCT and SOT recipients did not
have a statistically significant difference in mortality,
when compared to non-transplant patients. In fact,
HSCT recipients had a lower mortality (4.9%) than
either SOT recipients (10.9%) or non-transplant patients
(6.6%). Although previous studies have not shown a
significant attributable mortality to RSV infection in
SOT recipients, recent studies of HSCT recipients with
RSV LRTI have demonstrated mortality rates of 30–50%
(9–13), and in elderly populations RSV infection may
lead to 10,000 deaths annually (25). Several factors may
have led to a relatively low mortality among the HSCT
recipients in our study. HSCT patients were less likely
to have LRTI at the time of admission than were other
patients admitted with RSV infection, perhaps owing to
clinical awareness of increased mortality risk from
respiratory infections in this population, thereby lead-
ing to a lower threshold for admission for respiratory
infection by healthcare providers, and to more frequent
screening in the outpatient setting. The SOT and non-
transplant cohorts may also have been at higher risk for
mortality for reasons unrelated to transplantation
status, such as age and chronic lung disease.
Mortality from RSV in the general population has
been demonstrated to disproportionately affect the
elderly population, with nearly 80% of deaths occurring
in patients >65 years of age (25). Within the elderly
population with RSV infection, chronic lung disease has
been demonstrated as a risk factor for hospitalization
(4). In this study, the non-transplant cohort had a mean
age of 62 years, significantly older than the HSCT
cohort. Likewise, both the SOT cohort and non-trans-
plant cohort both had significantly higher prevalence of
chronic lung disease, potentially contributing to the
higher observed mortality rates.
Our study was unable to determine if aerosolized or
oral ribavirin had an impact on the overall mortality of
RSV in LRTI, or in the HSCT cohort alone. In the study,
over half the HSCT patients received ribavirin therapy,
compared with only 21% of SOT recipients and 9% of
Logistic regression model for death in all inpatients (n = 174)
Parameter
Odds ratio (95%
confidence interval) P-value
Gender = male (vs. female) 3.317 (0.605, 18.195) 0.1674
Age >60* (vs. age ≤60) 8.413 (1.429, 49.524) 0.0185
Lymphocyte count (per 100
unit increase)
0.866 (0.749, 1.001) 0.0512
Stem cell transplant (vs. no
transplant)
0.595 (0.086, 4.115) 0.5988
Solid organ transplant (vs.
no transplant)
0.414 (0.049, 3.496) 0.4178
Chronic lung disease
(vs. absent)
1.146 (0.207, 6.346) 0.8760
Fever (vs. absent) 1.298 (0.292, 5.773) 0.7317
No abnormal CT findings
(vs. ≥1 finding)
0.282 (0.052, 1.526) 0.1417
Lower respiratory infection
(vs. upper)
2.160 (0.192, 24.314) 0.5331
*Significant P < 0.05.
CT, computed tomography.
Table 2
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non-transplant patients. This difference is mostly a
reflection of institutional policy, which restricts inhaled
ribavirin to patients with a recent HSCT or with chronic
graft-versus-host disease requiring immunosuppressive
therapy. The efficacy of ribavirin for RSV infection
remains controversial, although off-label use in HSCT
and in heart and lung transplant recipients is common.
The only randomized-controlled trial of ribavirin in
HSCT recipients with RSV URTI was not able to
definitively demonstrate efficacy, owing to low patient
accrual (23). However, observational studies in HSCT
recipients have shown oral and aerosolized ribavirin to
be well tolerated, to prevent progression of URTI to
LRTI, and to decrease mortality in LRTI (9, 13, 26).
Several drugs are currently in the early stages of
development for the treatment of RSV, but have not yet
received U.S. Food and Drug Administration approval.
Compounds are being developed that prevent RSV from
fusing with host cell surfaces by targeting the RSV F
protein. Other compounds inhibit the RSV polymerase
or bind to the N-terminal region of nucleocapsid protein
(27). Monoclonal antibodies have not been shown to
have significant clinical activity when studied in
children (28).
Our study has several limitations. As with most
retrospective studies, incomplete or missing data may
affect study statistics and outcome measures. Also, as
testing for RSV is not mandatory for all adult patients
with influenza-like illness at our institution, it is possible
that some RSV infections in hospitalized patients were
not detected, and therefore not included in the study.
Similarly, as many patients transplanted at our institu-
tion receive acute care closer to their homes, some RSV
infections in these populations may have been missed.
Another important point is that no significant conclu-
sions can be made about the treatment effects of oral or
inhaled ribavirin for this hospitalized population,
because these therapies were not administered in a
consistent manner to any of the patient cohorts. Lack of
a historical control group also limits assessment of
efficacy of this treatment in the patients who received
therapy during this study. Finally, the sample size of
this study, while larger than many other descriptive
studies of RSV infection in immunocompromised hosts,
may have lacked the power necessary to identify
certain risk factors for mortality.
In conclusion, this study did not identify any significant
degree of increased mortality or morbidity associated
with RSV infection in hospitalized adult HSCT or SOT
recipients vs. non-transplant adult patients. We did
demonstrate, however, that increased age and low ALCs
are important risk factors for mortality in non-transplant
patients, consistent with other prior studies. Although
we cannot exclude the possibility of a beneficial treat-
ment effect of ribavirin in the HSCT cohort, our results
did not demonstrate decreased mortality in any specific
patient cohort treated with ribavirin. Newer antiviral
therapies for RSV are also in development and currently
undergoing clinical trials in immunocompromised pop-
ulations (29). Our results suggest that inclusion of
certain non-transplant patients in future trials may be of
benefit, with particular attention to patients with age >60,
who are at high risk of complications fromRSV infection.
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